Penny Stock Pick Report alerts investors on Top Stocks that would help investors to generate higher than average returns. Subscribe to
GTx, Inc. (NASDAQ:GTXI) was one of the most active losers in today`s trading sessions as it declined over 49.22% to close at $4.56 on huge volume of 7.63 million shares after the company announced that it has received a Complete Response Letter issued by the United States Food and Drug Administration regarding its New Drug Application for toremifene 80 mg to reduce fractures in men with prostate cancer receiving androgen deprivation therapy. The FDA identified two deficiencies in the Complete Response Letter and recommended that the following information be provided to the FDA to address these clinical deficiencies.
CEL-SCI Corporation (AMEX:CVM) declined 12.38% to end the day at $0.920 on huge volume of 5.54 million shares after the company filed to offer up to $10 million in various securities. The company may offer from time to time shares of common stock, preferred stock, convertible preferred stock, promissory notes, convertible notes, rights, warrants, or securities issuable upon the exercise of warrants at an initial offering price not to exceed $10,000,000, at prices and on terms to be determined at or prior to the time of sale in light of market conditions at the time of sale.
Hemispherx BioPharma, Inc (AMEX:HEB) decreased 8.28% to close at $1.33 on over 2.40 million shares after the company announced a two-prong Chronic Fatigue Syndrome clinical mission for November and December 2009. The Company plans to widen its ongoing clinical programs in CFS by accelerating collaborations with a consortium of researchers who have just discovered a retroviral link to Chronic Fatigue Syndrome.
